Sysmex Norge
Menu

Scientific Calendar October 2018

What is the aim of a sentinel lymph node biopsy procedure during early cancer treatment?

Identify the lymph nodes with the highest blood circulation

Identify the lymph nodes with the highest potential for harbouring metastases

Identify the lymph nodes with the highest calcium concentration

Congratulations!

That's the correct answer!

Sorry! That´s not completely correct!

Please try again

Sorry! That's not the correct answer!

Please try again

Notice

Please select at least one answer

Scientific background information

The main reason why patients die of cancer is that the cancer cells spread to form secondary tumours, or metastases, in vital organs such as the lungs and liver. A route frequently used by cancer cells is the lymphatic system. In many cancer types, like breast and prostate cancer, lymph nodes are typically the first sites where secondary tumours form, due to their natural filtration function.

For this reason, many treatments for early-stage cancer involve a procedure called ‘sentinel lymph node biopsy’, or SLNB. This method identifies the lymph nodes with the highest potential for harbouring metastases and helps to determine the nodal stage of the cancer to make informed decisions for surgery and subsequent treatment.

Standard SLNB uses radioisotopes for sentinel node localisation. Sysmex offers the Sentimag® / MagtraceTM system - an effective clinical solution that uses safe magnetic fields instead. This eliminates concerns related to the safety, workflow and availability associated with ionising radiation.

Since it was launched at the end of 2012, the system has been used to treat over 30,000 patients and has produced a strong base of clinical results that confirms its safety and efficacy in sentinel node localisation, a vital part of nodal cancer staging. [1-4]

References

1] Alvarado et al. (2017): SentimagIC: A non-inferiority trial comparing superparamagnetic iron oxide with Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer. Cancer Res. 77(4 suppl): P2-01-11.

[2] Karakatsanis et al. (2016): The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc99 and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. Breast Cancer Res Treat. 157(2): 281-294.

[3] Teshome et al. (2016): Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis. Ann Surg Oncol. 23 (5): 1508 – 14.

[4] Winter et al. (2017): Magnetic Marking and Intraoperative Detection of Primary Draining Lymph Nodes in High-Risk Prostate Cancer Using Superparamagnetic Iron Oxide Nanoparticles: Additional Diagnostic Value. Molecules. 22(12), 2192.

Endomag® and Sentimag® are registered European Union trademarks of Endomagnetics Ltd. www.endomag.com
Magtrace® is a registered trademark of Endomagnetics Ltd in the United Kingdom www.endomag.com

Copyright © Sysmex Europe GmbH. All rights reserved.
Customize your experience

We use cookies to enable you to optimally use our Website and to improve our communication with you. We shall take your selection into account and use only the data for which you give us your consent.

* May lead to restrictions in content and in the user experience
Detail about cookies
Essential cookies
These cookies help to make our website usable by enabling basic features such as page navigation and access to secure areas of our website. Our website cannot function properly without these cookies.
Statistics cookies
By collecting information anonymously, these cookies help us to understand how visitors interact with our website. This information enables us to continually improve our platform.
Marketing cookies
are used to track visitors on websites. The intention is to show advertisements that are relevant and appealing to the individual user and are, therefore, valuable to publishers and third-party advertisers.